Agree. We need to view debt in context of where it was in the past and not that it was zero in the previous report. (See previous debt to equity analysis in Post #:66113534 )
Still digesting the results but I'm pleasantly surprised by the market reaction today. I'm not complaining. Still early but If I have to guess the re-rate is driven by how cheap ACL is compared to peers (as discussed in Post #:66113534), the markets forward looking aspect on the non-Covid revenue growth of +20% (+7% ex Medlab), or +22% (9% ex-Medlab) when compared to pro forma 1H20 (ie, pre-Covid). Non-Covid revenue in Jan-23 of +22% of pcp.... those are good numbers
This is enough to convince me and hopefully the market of future profitability via increased market share and/or a larger industry moving forward. Looking at the Medicare numbers the latter being more likely and all that is needed here is a mean reversion to pre-Covid Industry growth.
Why I think ACL is ridiculously cheap., page-87
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.63 |
Change
-0.180(6.41%) |
Mkt cap ! $530.8M | |||
| Open | High | Low | Value | Volume |
| $2.82 | $2.85 | $2.61 | $1.767M | 659.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 18246 | $2.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.65 | 9719 | 1 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| ACL (ASX) Chart |